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A patient specific quality assurance program has been developed to facilitate the
clinical implementation of intensity modulated radiotherapy ~IMRT! delivered us-
ing a micro-multileaf collimator. The methodology includes several dosimetric
tasks that are performed prior to the treatment of each patient. Film dosimetry is
performed for each individual field and for the multifield composite plan. Indi-
vidual field measurements are performed at a depth of 5 cm in a water equivalent
slab phantom; export of dose calculations from the treatment planning system is
similarly specified. For the composite distribution, parameters from the patient plan
are applied to an IMRT phantom, and film is exposed in an axial orientation.
Distributions are compared with the aid of software developed for the specific
tasks. The measured and calculated dose distributions can be superimposed and
positioned graphically using move, rotate, and mirror tools, as well as by specifying
isocenter coordinates and using fiducial marks. Horizontal and vertical profiles are
available for analysis. Dose difference, distance-to-agreement, and g index, the
minimum scaled multidimensional distance between a measurement and a calcula-
tion point determined in combined dose and physical distance space, are calculated
along a specified isodose line and displayed. g provides an excellent measure of
disagreement between measurement and calculation for complex intensity distribu-
tions. We specify 3% dose difference and 3 mm distance as our scaling acceptabil-
ity criteria. Absolute dosimetry for each composite plan is performed using an
ionization chamber. To date, excellent agreement between measurements and cal-
culations has been observed. © 2003 American College of Medical Physics.
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I. INTRODUCTION
The concept of conforming the dose in three-dimensions is not new; the use of compensators,
wedges, and dynamic asymmetric jaws is targeted toward that process. Intensity modulated radio-
therapy ~IMRT!, being conformal radiotherapy, has the same goal of conforming the physical dose
in three dimensions. The advancement of conformal therapy is one of the most promising devel-
opments to take place in radiotherapy during the past decade due to development of computer
applications in diagnostic imaging and radiotherapy. A number of studies have demonstrated the
superiority of the physical dose distribution of IMRT compared to other modalities, with applica-
tions in brain tumors, head and neck cancers, and prostate cancer treatments.1–5 The reason and
rationale for the effort put in this area is to reduce the risk or severity of complications where
radiotherapy is successful, and to escalate the dose while reducing or keeping a comparable level
of complications, where the failure of radiation therapy is the lack of local control.6–10
Conventional devices, such as wedges and compensators, modulate the intensity of a beam, and
subsequently the energy fluence, such that all points in a field are continuously irradiated, hence40 1526-9914Õ2003Õ41Õ40Õ11Õ$17.00 © 2003 Am. Coll. Med. Phys. 40
41 Agazaryan, Solberg, and DeMarco: Patient specific quality assurance . . . 41the term spatial modulation. Another method of varying the energy fluence distribution across the
field is through temporal modulation. During this process, the energy fluence modulation is
achieved not by modulating the intensity of the beam across the field, but rather by modulating the
time that each subpart of a field is exposed to radiation. An example of this is a process called
dynamic wedging, during which the jaw moves uniformly while the radiation beam is on, pro-
ducing a wedge-shaped dose distribution.11–13 Multileaf collimator ~MLC! intensity modulated
radiation therapy is an advanced form of conformal therapy. With the use of a multileaf collimator,
the exposure time of different sections of the field to primary radiation is modulated in two
dimensions, resulting in two-dimensional energy fluence modulations across the field.
Dosimetric accuracy requirements have been developed for ‘‘conventional’’ treatments.14 Dose
distributions are analyzed based on dose gradients. Low dose gradient regions are required to meet
the acceptance criteria placed on dose difference, and high dose gradient regions are required to
meet the acceptance criteria placed on distance-to-agreement ~DTA!. Tolerance levels for photon
beam calculations in homogeneous media are 3% and 4 mm, respectively. While techniques to
calculate and deliver IMRT are presently reaching a level of maturity within the academic and
clinical communities, methods for direct verification of the delivery, as well as definitions of
acceptability of a treatment in terms of these measurements, are the most problematic at this stage
of IMRT advancement.
Patient specific dosimetric verification of an IMRT plan is an important part of clinical imple-
mentation of IMRT into any clinic. A number of IMRT quality assurance ~QA! studies have been
published recently that address the issue of IMRT QA and in some cases patient specific QA.14 –22
The approach taken at our institution shares some similarities with the above-mentioned publica-
tions, however, the approach has many differences in terms of methodology, equipment, measure-
ments, and especially methods of measurement analysis.
II. MATERIALS AND METHODS
A. IMRT software and hardware
The measurements presented have been conducted with the use of the Novalis® linear accel-
erator ~BrainLAB, AG, Heimstetten, Germany!. The underlying accelerator is a Varian Clinac®
FIG. 1. ~Color! ~Left! Schematic diagram of the experimental setups of Radiology Support Devices ~RSD! Dry Water™
Slab phantom used for single field IMRT measurements. ~Right! A picture of a single field IMRT measurement setup.Journal of Applied Clinical Medical Physics, Vol. 4, No. 1, Winter 2003
42 Agazaryan, Solberg, and DeMarco: Patient specific quality assurance . . . 42600SR unit ~Varian Associates, Palo Alto, CA!, a C-Series linear accelerator generating a 6 MV
x-ray beam. The dose rate is variable in four equal increments of 160 MU/min. The minimum dose
rate is 160 MU/min and maximum dose rate is 800 MU/min. The dose rate for IMRT treatments
is set to 480 MU/min.
The Novalis® is equipped with an m3™ ~BrainLAB, AG, Heimstetten, Germany! micro-
multileaf collimator ~mMLC!. The mMLC is an accessory for Varian C-Series radiotherapy ma-
FIG. 2. ~Color! The MED-TEC IMRT phantom made of Virtual Water™ during the absolute dose measurement.
FIG. 3. ~Color! The treatment planning system has an option of mapping the complete patient treatment onto any phantom.
A seven field prostate IMRT plan is shown mapped onto the MED-TEC IMRT phantom.Journal of Applied Clinical Medical Physics, Vol. 4, No. 1, Winter 2003
43 Agazaryan, Solberg, and DeMarco: Patient specific quality assurance . . . 43chines. The m3™ micro-MLC consists of fifty-two tungsten leaves that shape a treatment field of
up to 10310 cm2.23 The leaf widths range from 3.0 mm at the center of the field to 5.5 mm at the
periphery. The MLC consists of fourteen 3.0 mm wide, six 4.5 mm wide, and six 5.5 mm wide leaf
pairs. The front faces of the leaves are shaped to minimize the penumbra variations as a function
of position. Maximum distance over centerline is 5.0 cm, maximum retract distance is 5.0 cm, and
maximum leaf spread is 10.0 cm. The specification for maximum leaf speed is 1.5 cm/s and the
specification for the leaf positioning accuracy is better than 0.1 mm. The system is capable of
dynamic and segmented IMRT, however, only segmented IMRT is used clinically at our institu-
tion.
IMRT plans presented have been generated using commercially available IMRT treatment
planning system ~BrainSCAN® version 5, BrainLAB AG, Heimstetten, Germany!. This micro-
MLC based intensity modulated radiation surgery ~IMRS! system is BrainLAB’s high-resolution
version of IMRT. The inverse planning algorithm is based on the dynamically penalized likelihood
~DPL! algorithm. The algorithm itself is based on a maximum likelihood estimator ~MLE! method
of statistical parameter estimation used initially in image reconstruction. The relationship between
the MLE and DPL is described in detail by Llacer.24 The target function used in the algorithm is
adapted from a PET image reconstruction algorithm developed by Shepp and Vardi.25,26 The
algorithm is robust in that it will always produce reasonable results.
B. Dry Water™ Slab and MED-TEC IMRT phantom dosimetry
Film dosimetry has been used in this study. Film measurements have been conducted with a
Radiology Support Devices ~RSD! Dry Water™ Slab phantom ~RSD, Long Beach, CA!, the
experimental setup of which is shown in Fig. 1, and a MED-TEC IMRT phantom made from
Virtual Water™ ~MED-TEC, Orange City, IA! shown in Fig. 2. Dry Water™ and Virtual Water™
phantoms meet International Commission on Radiation Units and Measurements Report 44 ~ICRU
44! guidelines.27 Film dosimetry is a standard method of obtaining two-dimensional dose
distributions.28–30 Because the accuracy and precision of the film measurements are dependent on
measurement conditions and processing, film dosimetry is not a reliable method of absolute
measurements, however, it is a valuable tool for relative measurements and periodic quality
assurance measurements.31
IMRT patient specific QA requires a method of absolute dose measurements. The ionization
chamber is the standard dosimeter for calibration and absolute dose measurement for radiation
therapy.32,33 As such, a 0.125cc ionization chamber ~Semiflex Model 31002, PTW, Freiburg,
Germany! has been used for absolute dose measurements in the MED-TEC IMRT phantom.
C. A software tool for quantitative comparative analysis
A software tool has been developed to perform quantitative comparative analysis of two
datasets. This in-house software is written in a development language ~IDL, Research Systems,
Inc., Boulder, CO! and runs on Microsoft® Windows® ~Microsoft Corp., Redmond, WA! envi-
ronment. The tool is used as a platform for comparative analysis of the measured and calculated
dose distributions. The measured and calculated dose distribution maps can be superimposed and
positioned manually using move, rotate, and mirror tools. Absolute positioning is also available by
specifying the isocenter coordinates from a treatment planning dataset and specifying two pairs of
marks on the film, defining two lines, the crossing point of which defines the isocenter on the film.
Dose difference, distance-to-agreement, and g index introduced by Low et al. along any specified
isodose line can be displayed.34 Horizontal and vertical profiles of these quantities through any
specified point of the dose distribution map and two-dimensional map of the g index are available.
The g index is the minimum scaled multidimensional distance between a measurement and a
calculation point, determined in combined dose and physical distance space. The scaling param-
eters of dose difference and distance are user inputs. For clinical patient specific QA we specifyJournal of Applied Clinical Medical Physics, Vol. 4, No. 1, Winter 2003
44 Agazaryan, Solberg, and DeMarco: Patient specific quality assurance . . . 443% dose difference and 3 mm distance acceptance scaling criteria.14 The magnitude of g provides
a measure of disagreement between measurement and calculation. Regions where g is larger than
unity correspond to locations where the calculation does not meet the acceptance criteria. Analysis
of the single field IMRT measurements using a Dry Water™ Slab phantom and the composite plan
measurement using a MED-TEC IMRT phantom are performed with the help of the software. All
the results of the analysis of the data are printed and/or saved in a postscript file.
D. Patient specific quality assurance protocol
We have developed a patient specific QA protocol for IMRT patient pretreatment verification.
The protocol consists of two parts: absolute dosimetry and relative dosimetry. The film measure-
ments are primarily concerned with investigating the relative dosimetric agreement between the
planned and measured dose distributions. They provide important information about overall dis-
tribution in a particular plane. In addition, ion chamber verification provides information about
absolute agreement at a point.
The protocol developed for IMRT patient treatment verification is as follows. All fields are
individually delivered and measured in the Dry Water™ Slab phantom with an SAD setup shown
in Fig. 1 at 5.0 cm depth. For individual fields Kodak XV2 ~Eastman Kodak, Rochester, NY! film
is used and monitor units ~MU! are scaled to avoid film saturation. Monitor unit scaling does not
change the dynamics of the MLC movements, since the clinical cases are being delivered using
segmented IMRT. In addition, the composite plan is delivered onto the MED-TEC IMRT phantom
shown in Fig. 2 and axial dose distribution is measured using Kodak EDR2 ~Eastman Kodak,
Rochester, NY! film, where the isocenter is positioned at the film plane. The composite film
measurement is in the plane of the leaf movements and is largely affected only by the leaf pairs
corresponding to that plane and neighboring pairs. Besides being more sensitive measurements,
the single field measurements provide QA for all the leaf pairs. Additionally, absolute dosimetry
for each composite plan is performed using an ionization chamber, with the ion chamber posi-
tioned at isocenter. The center of the ion chamber sensitive volume is located 3.8 cm lateral from
the center of the most superior MED-TEC IMRT phantom slab.
FIG. 4. ~Color! The 20%, 50%, and 80% isodose lines of calculation and measurement are shown. Measured data is in the
form of color wash, and calculated data is presented in terms of solid lines. The g index distribution is superimposed on
the calculated and measured dose maps. For the regions where the g index is larger than unity, the program outputs a map
of g index with different intensities of green corresponding to different magnitudes of g. Values of 3% and 3 mm have been
used for dose difference and distance tolerances respectively. ~Left! An example of a QA analysis with significant differ-
ence between measurement and calculation. ~Right! An example of a QA analysis with no points on the map with g index
larger than unity.Journal of Applied Clinical Medical Physics, Vol. 4, No. 1, Winter 2003
45 Agazaryan, Solberg, and DeMarco: Patient specific quality assurance . . . 45Pixel gray scale value to dose conversion of the XV2 and EDR2 film data is performed using
the sensitometric curves obtained from calibration films. Calibration films are obtained by expos-
ing a series of XV2 and EDR2 films to 10 by 10 cm2 fields at 1.5 cm depth and 98.5 cm source
to surface distance ~SSD! in Dry Water™ over the useful range of each type of film. The calibra-
tion technique ignores any depth variation of the film response, which has been shown to be
minimal for up to field sizes of 10 by 10 cm2.35
The film measurements are compared with the planned dose distribution using the described
in-house software. The treatment planning system has an option of exporting dose distribution at
specified depth assuming a cubic water phantom, allowing for IMRT single field dose measure-
ment and calculation comparisons.
The MED-TEC IMRT phantom, made of Virtual Water™ and shown in Fig. 2, is computed
tomography ~CT! compatible with visible fiducial markers. The phantom is scanned on a CT
scanner and the images are transferred to the treatment planning system. The treatment planning
system has an option of mapping the complete patient treatment onto any phantom ~Fig. 3!. After
mapping the patient treatment plan onto the MED-TEC phantom, the dose distribution in the
phantom can be viewed and exported. The exported distribution is then compared to the measured
distribution with our in-house software discussed previously. The MED-TEC IMRT Phantom
became an essential part of quality assurance at our institution.
In Figs. 4–8, sample analysis of single field measurements are shown. The program outputs the
FIG. 5. ~Color! ~Top! Horizontal and ~bottom! vertical profiles of measured and calculated dose distribution along with the
g index. The example shown is from the data presented in Fig. 4, right.Journal of Applied Clinical Medical Physics, Vol. 4, No. 1, Winter 2003
46 Agazaryan, Solberg, and DeMarco: Patient specific quality assurance . . . 4620%, 50%, and 80% isodose lines of calculation and measurement, as shown in Fig. 4. Measured
data is in the form of color wash, and calculated data is presented in terms of solid lines. The g
index distribution is superimposed on the calculated and measured dose maps. For the regions
where the g index is larger than unity, the program outputs a map of the g index with different
intensities of green corresponding to different magnitudes of g. Values of 3% and 3 mm are used
for dose difference and distance tolerances, respectively. Horizontal and vertical profiles of mea-
sured and calculated data, along with the g index, at any point of the dose distribution are
interactively available ~Fig. 5!. DTA values along any specified isodose line of the calculation data
can be displayed as shown in Fig. 6. Film readings ~Fig. 7!, as well as g values ~Fig. 8!, along the
same specified isodose line of the calculation data are also displayed, printed, and/or saved in a
postscript file.
FIG. 6. DTA values along the specified ~80%! isodose line of the calculation data. The average DTA is less than 0.5 mm
and the maximum DTA is less than 2.0 min.
FIG. 7. ~Color! Film reading along the specified ~80%! isodose line of the calculation data.
FIG. 8. ~Color! Gamma index values along the specified ~80%! isodose line of the calculation data.Journal of Applied Clinical Medical Physics, Vol. 4, No. 1, Winter 2003
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The analysis tool described is currently being used for IMRT patient specific verification at the
UCLA Radiation Oncology department and has proven to be a valuable tool for analyzing the
single field measurements using a Dry Water™ Slab phantom and the composite plan measure-
ments using a MED-TEC IMRT phantom. In addition, other researchers at our institution use this
software to compare datasets. In one study, the tool is being used to compare brachytherapy Monte
Carlo calculation with TG-43 based calculations. In another study, the tool is being used to
compare IMRT measurements with and without respiratory gating.
A comparison of the single field IMRT measurement and calculation as well as comparison of
composite plan film measurement with calculation has been performed for every patient treated
with IMRT. In general, larger dose difference regions correspond to smaller DTA value regions
and vice versa. This is expected, since larger dose differences are expected at high dose gradient
regions, where the involved distances are small. An example of a typical composite IMRT film
measurement analysis is shown in Fig. 9.
The agreement between measurement and calculation of composite plan absolute dose has been
performed with an ion chamber since the sixth patient treated with IMRT. For only three of these
patients the ion chamber has not been positioned at the isocenter since the isocenter position was
near the edge of the planning target volume ~PTV!. The summary of the measured and calculated
absolute dose differences for all patients is presented in Table I. The histogram of this data is
shown in Fig. 10. The largest error measured so far has been 24.79%, with a mean of only
20.54% and standard deviation of 1.54%. Considering that the reported uncertainty of ion cham-
ber calibration itself is 1.2%, the absolute measurement data is well within the acceptable range.
The distribution is very symmetric with a skewness of only 0.07. The data is leptokurtic with a
kurtosis of 0.6. The latter means that the center peak around the mean of the distribution is higher
than that for a normal distribution.
According to our institutional standard of 63% acceptability criteria, the treatment plan with
the measured error of 24.79% was not acceptable for treatment until it was investigated further
FIG. 9. ~Color! 20%, 50%, and 80% isodose lines of calculation and measurement of a composite seven field IMRT plan.
Measured data is in the form of color wash, and calculated data is in terms of solid lines. The g index distribution is
superimposed on the map using different intensities of green for different magnitudes of gamma.Journal of Applied Clinical Medical Physics, Vol. 4, No. 1, Winter 2003
48 Agazaryan, Solberg, and DeMarco: Patient specific quality assurance . . . 48and found that the disagreement occurred due to the volume averaging effect of a finite-size ion
chamber. This was a treatment plan with unusually large intensity modulations in the direction
perpendicular to leaf motion. Although the cumulative dose distribution did not exhibit a large
dose gradient at the isocenter, the dose distributions from individual fields did. The above-
mentioned fact has been identified for several treatment plans with a large disagreement between
calculated and measured absolute doses. For these cases, measurements at less intensity modulated
regions yielded better results.
The negative to positive ratio of the absolute dose data is 1.75, and the mean dose difference is
a negative number ~Table I!. We suspect that the reason for the above two facts is volume
averaging effect of an ion chamber. During IMRT treatment there are instances where the ion
chamber is partially irradiated with primary beam and the displayed reading is a volume-averaged
reading, giving a slightly lower reading.
The dosimetric verification protocol and the software tools used for the analysis of the data
discussed are shown to be highly practical. The measurements and the analysis demonstrate that
the complete IMRT system at use is accurate and acceptable for patient treatments.
FIG. 10. ~Color! The histogram of the measured and calculated absolute dose differences for all the patients since estab-
lishing the QA protocol.
TABLE I. The statistical analysis of the percent difference between the calculated and measured absolute doses for all the
patients since establishing the QA protocol.
Descriptive statistic for absolute dosimetry data ~Patients 6–60!
Mean À0.54
Standard Error 0.21
Median 20.59
Mode 20.71
Standard Deviation 1.54
Sample Variance 2.37
Kurtosis 0.67
Skewness 20.07
Range 8.32
Minimum À4.79
Maximum 3.53
Count 55
Number of Negatives 35
Number of Positives 20
Negative to Positive Ratio 1.75
Confidence Level 95.0% 0.42Journal of Applied Clinical Medical Physics, Vol. 4, No. 1, Winter 2003
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